Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.

Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-196.

Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector. Our top performers in the energy and financials sectors were NOV, a provider of oilfield equipment, technology and expertise, and First Citizens, a North Carolina-based bank. Our largest new purchase was Houston-headquartered Prosperity BancShares, the fifth-largest bank in Texas.